<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148758</url>
  </required_header>
  <id_info>
    <org_study_id>BP22909</org_study_id>
    <secondary_id>2009-016014-25</secondary_id>
    <nct_id>NCT01148758</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer</brief_title>
  <official_title>Open-label, Exploratory, Pharmacodynamic (PD) Dose-finding Study of Intravenous RO5323441 in Patients With Metastatic Treatment-refractory Colorectal and Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This exploratory, open label study will assess the the dose-effect relationship, efficacy and
      safety of RO5323441 in patients with metastatic treatment-refractory colorectal or ovarian
      cancer. Cohorts of patients will receive doses of intravenous RO5323441 in the range of 25mg
      to 3g every 1 or 2 weeks and will undergo serial dynamic contrast-enhanced magnetic resonance
      imaging (DCE-MRI) assessments. In the absence of disease progression and unacceptable
      toxicity, patients may continue to receive their maximum dose of RO5323441 for a core
      treatment phase of up to a total of 6 months. Treatment with RO5323441 can be extended at the
      investigator's discretion until disease progression or unacceptable toxicity occurs. Target
      sample size is &lt;100.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RO5323441 concentration - pharmacodynamic effect relationship using DCE-MRI</measure>
    <time_frame>up to 19.5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of within-patient dose escalation</measure>
    <time_frame>from baseline to Day 127 (+/-3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional DCE-MRI effects (time-course of DCE-MRI effects, test-retest reproducibility)</measure>
    <time_frame>up to 19.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Candidate biomarkers associated with PD effect of RO5323441</measure>
    <time_frame>up to 19.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: maximum and trough concentrations of RO5323441</measure>
    <time_frame>up to 19.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: Adverse events, vital signs, laboratory parameters</measure>
    <time_frame>up to 19.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: ORR, duration of response, progression-free survival according to RECIST criteria, CTI/MRI assessments</measure>
    <time_frame>up to 19.5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Colorectal Cancer, Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5323441</intervention_name>
    <description>cohorts receiving multiple doses iv</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;/=19 years of age

          -  metastatic or unresectable colorectal or ovarian cancer refractory to, or unsuitable
             for standard therapy

          -  presence of tumor lesions suitable for DCE-MRI evaluation

          -  WHO performance status 0-1

          -  adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  patient unsuitable for MRI scanning (e.g. metal implants, pacemaker, claustrophobia,
             hypersensitivity to DCE-MRI contrast material)

          -  brain metastases

          -  clinically significant ascites

          -  active bleeding, bleeding diathesis, oral anti-vitamin K medication (other than low
             dose coumarin) or history of coagulation disorders

          -  radiation therapy within 3 weeks, or anti-neoplastic therapy &lt;30 days prior to first
             dose of study drug

          -  chronic therapy with systemic steroids or another immunosuppressive agent &lt;2 weeks
             prior to first dose of study drug

          -  treated with bevacizumab in last regimen of systemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M20 4QL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

